School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China.
Tianjin Pharmaceutical Research Institute, Tianjin 300072, PR China.
Pharmacol Res. 2022 Jul;181:106257. doi: 10.1016/j.phrs.2022.106257. Epub 2022 May 13.
Cardiac fibrosis is a pathogenic factor of many cardiovascular diseases (CVD), which seriously affects people's life and health, causing huge economic losses.Therefore, it is very significant to find an effective treatment for myocardial fibrosis. Adipokines are mainly derived from adipose tissue and have an prominent regulatory effect on glucose and lipid metabolism, inflammation, immune response and cardiovascular function. Adipose tissue is composed of a variety of cell types, including adipocytes, endothelial cells, macrophages and smooth muscle cells. Adipokines mainly include adiponectin, leptin, resistin, visfatin and omentin, which are synthesized and secreted by adipocytes. More and more evidence shows that adipokines can regulate the progress of cardiac fibrosis. This scientific review provides new ideas for targeting adipokines in the treatment of myocardial fibrosis and provides strategies for the development of new, safe, and effective pharmacological antagonists against myocardial fibrosis based on adipokines activity.
心肌纤维化是多种心血管疾病（CVD）的致病因素，严重影响人们的生活和健康，造成巨大的经济损失。因此，寻找有效的心肌纤维化治疗方法具有重要意义。脂肪细胞因子主要来源于脂肪组织，对糖脂代谢、炎症、免疫反应和心血管功能具有显著的调节作用。脂肪组织由多种细胞类型组成，包括脂肪细胞、内皮细胞、巨噬细胞和平滑肌细胞。脂肪细胞因子主要包括脂联素、瘦素、抵抗素、内脂素和网膜素，由脂肪细胞合成和分泌。越来越多的证据表明，脂肪细胞因子可以调节心肌纤维化的进展。本综述为针对脂肪细胞因子治疗心肌纤维化提供了新的思路，并为基于脂肪细胞因子活性开发新的、安全有效的心肌纤维化药理学拮抗剂提供了策略。
